Genetic predisposition of life-threatening antiepileptic-induced skin reactions

Oxcarbazepine-induced Stevens-Johnson Syndrome: A Case Report

(2009) Lung-Chang Lin et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients

(2009) Gbenga R. Kazeem et al.   Pharmacogenetics and Genomics

CNS Adverse Events Associated with Antiepileptic Drugs

(2008) Gina M Kennedy et al.   CNS DRUGS

Painful diabetic neuropathy: treatment and future aspects

(2008) Dan Ziegler   DIABETES-METABOLISM RESEARCH AND REVIEWS

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population

(2008) Chaichon Locharernkul et al.   EPILEPSIA

Cross-reactivity pattern of rash from current aromatic antiepileptic drugs

(2008) Silje Alvestad et al.   EPILEPSY RESEARCH

Oxcarbazepine-induced Stevens-Johnson syndrome in a patient withHLA-B*1502genotype

(2008) Y-C Chen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis

(2008) Wen-Hung Chung et al.   NATURE MEDICINE

Cross-sensitivity of skin rashes with antiepileptic drug use

(2008) L. J. Hirsch et al.   NEUROLOGY

A European study of HLA-B in Stevens???Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

(2008) Christine Lonjou et al.   Pharmacogenetics and Genomics

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis

(2008) Nahoko Kaniwa et al.   PHARMACOGENOMICS

Carbamazepine,HLA-B*1502and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations

(2008) P Brent Ferrell et al.   PHARMACOGENOMICS

Adverse Effects of Antiepileptic Drugs

(2008) Rafael Toledano et al.   SEMINARS IN NEUROLOGY

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study

(2007) Maja Mockenhaupt et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY